- Conditions
- Lymphoma
- Interventions
- rituximab, bortezomib, carmustine, cisplatin, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, melphalan, thalidomide, autologous-autologous tandem hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 29
- States / cities
- Hartford, Connecticut • Beech Grove, Indiana • Richmond, Indiana + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
- Interventions
- Laboratory Biomarker Analysis, Liposome-encapsulated Daunorubicin-Cytarabine
- Other · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 186
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
- Conditions
- Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Interventions
- Cytarabine, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis, Liposome-encapsulated Daunorubicin-Cytarabine, Pharmacological Study
- Drug · Biological · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
- Conditions
- Mantle Cell Lymphoma, Lymphoma
- Interventions
- Bendamustine, Rituximab, Cytarabine, Zanubrutinib, Sonrotoclax
- Drug
- Lead sponsor
- Christine Ryan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2039
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Boston, Massachusetts • Rochester, Minnesota + 2 more
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Interventions
- Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Mantle-Cell Lymphoma
- Interventions
- G-CSF, Rituximab, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Ifosfamide, Leucovorin, Mesna, Methotrexate, Vincristine
- Biological · Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Cytarabine, Daunorubicin, Etoposide, Clofarabine, CliniMACS
- Drug · Device
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 7
- States / cities
- Palo Alto, California • San Diego, California • Chicago, Illinois + 4 more
- Conditions
- Lymphoma
- Interventions
- aldesleukin, filgrastim, recombinant interferon gamma, carmustine, cyclosporine, cytarabine, etoposide, melphalan, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 53 more
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- asparaginase, cytarabine, daunorubicin hydrochloride, methotrexate, therapeutic hydrocortisone, thioguanine
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 209
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera, Secondary Acute Myeloid Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib
- Procedure · Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- Columbus, Ohio • Portland, Oregon • Dallas, Texas
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma
- Interventions
- DNR, VCR, PEG-asp, CTX, Prednisone, Liposomal AraC, MTX, LCV, AraC, Etoposide, Dasatinib, Rituximab, Hydrocortisone
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 4
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 1 more
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Liposome-encapsulated Daunorubicin-Cytarabine, Pomalidomide
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 11
- States / cities
- Atlanta, Georgia • Kansas City, Kansas • Westwood, Kansas + 8 more
- Conditions
- Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma, T-cell Leukemia, Recurrent Disease, Acute Leukemia
- Interventions
- Palbociclib, Cytarabine, Methotrexate, Hydrocortisone, Doxorubicin, Prednisolone, Vincristine, Pegaspargase, Prednisone
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 31 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Loma Linda, California • Orange, California + 15 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- Azacitidine, Decitabine, Cytarabine, Daunorubicin, Etoposide, ITMHA, Idarubicin, Fludarabine, Mitoxantrone, Erwinia asparaginase, Sorafenib, G-CSF, Dexrazoxane, Stem Cell Transplant, Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn
- Drug · Combination Product · Biological
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 29 Days to 21 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 10
- States / cities
- Madera, California • Orange, California • Palo Alto, California + 7 more
- Conditions
- Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Interventions
- Cytarabine, Decitabine, Idarubicin, Laboratory Biomarker Analysis, Liposome-encapsulated Daunorubicin-Cytarabine, Quality-of-Life Assessment, Questionnaire Administration, Azacitidine, Venetoclax, glasdegib
- Drug · Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
- Interventions
- Laboratory Biomarker Analysis, Liposomal Cytarabine-Daunorubicin CPX-351
- Other · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Seattle, Washington
- Conditions
- Acute Myeloid Leukemia, Pediatric AML
- Interventions
- Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C), Venetoclax, Etoposide, Asparaginase Erwinia Chrysanthemi (recombinant), Intrathecal triple, SOC
- Drug · Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Month to 30 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Cytarabine, Allogeneic stem cell transplant, Bone marrow aspiration, Punch skin biopsy, ClinSeq
- Drug · Procedure · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • St Louis, Missouri • Rochester, New York
- Conditions
- Recurrent Acute Myeloid Leukemia
- Interventions
- Enasidenib Mesylate, Liposome-encapsulated Daunorubicin-Cytarabine
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
- Interventions
- Velcade, Methotrexate, Methotrexate / Hydrocortisone / Cytarabine, Dexamethasone, Mitoxantrone, Vincristine, Pegaspargase
- Drug
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 1 Year to 39 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Relapsed Acute Myelogenous Leukemia
- Interventions
- Clofarabine, Etoposide, Cyclophosphamide, Filgrastim, Cytarabine
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Miami, Florida • Chicago, Illinois + 1 more
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Orange, California • Sacramento, California + 2 more